Which has preferable earnings and valuation, MRNA or LNTH?

Lantheus has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 16.70 -$2.82B -$8.15 N/A Lantheus $1.54B 4.34 $233.56M $4.15 24.78

Is MRNA or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -143.55% -26.64% -19.32% Lantheus 18.05% 29.32% 15.00%

Does the media refer more to MRNA or LNTH?

In the previous week, Moderna had 13 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Moderna and 1 mentions for Lantheus. Moderna's average media sentiment score of 0.61 beat Lantheus' score of -0.40 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 4 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LNTH or ROIV?

Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.34 $233.56M $4.15 24.78 Roivant Sciences $8.26M 3,081.71 -$299.77M -$0.60 N/A

Is LNTH or ROIV more profitable?

Lantheus has a net margin of 18.05% compared to Roivant Sciences' net margin of -3,629.19%. Lantheus' return on equity of 29.32% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media prefer LNTH or ROIV?

In the previous week, Roivant Sciences had 13 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Roivant Sciences and 1 mentions for Lantheus. Roivant Sciences' average media sentiment score of 0.49 beat Lantheus' score of -0.40 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, LNTH or BNTX?

Lantheus has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.34 $233.56M $4.15 24.78 BioNTech $3.25B 7.32 -$1.29B -$5.88 N/A

Is LNTH or BNTX more profitable?

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% BioNTech -44.39% -5.30% -4.62%

Does the media favor LNTH or BNTX?

In the previous week, BioNTech had 2 more articles in the media than Lantheus. MarketBeat recorded 3 mentions for BioNTech and 1 mentions for Lantheus. BioNTech's average media sentiment score of 0.29 beat Lantheus' score of -0.40 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, INSM or LNTH?

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 39.87 -$1.28B -$5.75 N/A Lantheus $1.54B 4.34 $233.56M $4.15 24.78

Is INSM or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Lantheus 18.05% 29.32% 15.00%

Does the media favor INSM or LNTH?

In the previous week, Insmed had 4 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Insmed and 1 mentions for Lantheus. Insmed's average media sentiment score of 1.44 beat Lantheus' score of -0.40 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, LNTH or VTRS?

Lantheus has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.34 $233.56M $4.15 24.78 Viatris $14.30B 1.37 -$3.51B -$0.26 N/A

Is LNTH or VTRS more profitable?

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Viatris -2.04% 19.04% 7.62%

Does the media prefer LNTH or VTRS?

In the previous week, Viatris had 8 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Viatris and 1 mentions for Lantheus. Viatris' average media sentiment score of 0.82 beat Lantheus' score of -0.40 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lantheus (LNTH) Competitors

$102.82 -7.07 (-6.43%)

Closing price 04:00 PM Eastern

Extended Trading

$100.50 -2.32 (-2.25%)

As of 07:59 PM Eastern

Compare

LNTH vs. MRNA, ROIV, BNTX, INSM, and VTRS

Should you buy Lantheus stock or one of its competitors? MarketBeat compares Lantheus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lantheus include Moderna (MRNA), Roivant Sciences (ROIV), BioNTech (BNTX), Insmed (INSM), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does Lantheus compare to Moderna?

Moderna (NASDAQ:MRNA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

75.3% of Moderna shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Moderna had 13 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Moderna and 1 mentions for Lantheus. Moderna's average media sentiment score of 0.61 beat Lantheus' score of -0.40 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	4 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 18.05% compared to Moderna's net margin of -143.55%. Lantheus' return on equity of 29.32% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Lantheus	18.05%	29.32%	15.00%

Lantheus has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	16.70	-$2.82B	-$8.15	N/A
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78

Moderna presently has a consensus price target of $37.13, suggesting a potential downside of 54.60%. Lantheus has a consensus price target of $101.86, suggesting a potential downside of 0.94%. Given Lantheus' stronger consensus rating and higher probable upside, analysts clearly believe Lantheus is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Lantheus beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Lantheus compare to Roivant Sciences?

Lantheus (NASDAQ:LNTH) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Lantheus currently has a consensus target price of $101.86, suggesting a potential downside of 0.94%. Roivant Sciences has a consensus target price of $33.59, suggesting a potential downside of 5.08%. Given Lantheus' higher possible upside, research analysts plainly believe Lantheus is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

In the previous week, Roivant Sciences had 13 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Roivant Sciences and 1 mentions for Lantheus. Roivant Sciences' average media sentiment score of 0.49 beat Lantheus' score of -0.40 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.1% of Lantheus shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
Roivant Sciences	$8.26M	3,081.71	-$299.77M	-$0.60	N/A

Lantheus has a net margin of 18.05% compared to Roivant Sciences' net margin of -3,629.19%. Lantheus' return on equity of 29.32% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

Lantheus beats Roivant Sciences on 8 of the 15 factors compared between the two stocks.

How does Lantheus compare to BioNTech?

Lantheus (NASDAQ:LNTH) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Lantheus presently has a consensus target price of $101.86, suggesting a potential downside of 0.94%. BioNTech has a consensus target price of $129.56, suggesting a potential upside of 37.94%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, BioNTech had 2 more articles in the media than Lantheus. MarketBeat recorded 3 mentions for BioNTech and 1 mentions for Lantheus. BioNTech's average media sentiment score of 0.29 beat Lantheus' score of -0.40 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 19.2% of BioNTech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to BioNTech's net margin of -44.39%. Lantheus' return on equity of 29.32% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
BioNTech	-44.39%	-5.30%	-4.62%

Lantheus has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
BioNTech	$3.25B	7.32	-$1.29B	-$5.88	N/A

Summary

BioNTech beats Lantheus on 10 of the 17 factors compared between the two stocks.

How does Lantheus compare to Insmed?

Insmed (NASDAQ:INSM) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Lantheus has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.87	-$1.28B	-$5.75	N/A
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78

99.1% of Lantheus shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Insmed had 4 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Insmed and 1 mentions for Lantheus. Insmed's average media sentiment score of 1.44 beat Lantheus' score of -0.40 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed presently has a consensus target price of $211.86, suggesting a potential upside of 89.94%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 0.94%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Lantheus has a net margin of 18.05% compared to Insmed's net margin of -144.44%. Lantheus' return on equity of 29.32% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Lantheus	18.05%	29.32%	15.00%

Insmed has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Summary

Insmed beats Lantheus on 9 of the 17 factors compared between the two stocks.

How does Lantheus compare to Viatris?

Lantheus (NASDAQ:LNTH) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Lantheus has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
Viatris	$14.30B	1.37	-$3.51B	-$0.26	N/A

Lantheus presently has a consensus price target of $101.86, indicating a potential downside of 0.94%. Viatris has a consensus price target of $17.50, indicating a potential upside of 4.17%. Given Viatris' higher probable upside, analysts clearly believe Viatris is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Viatris had 8 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Viatris and 1 mentions for Lantheus. Viatris' average media sentiment score of 0.82 beat Lantheus' score of -0.40 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a net margin of 18.05% compared to Viatris' net margin of -2.04%. Lantheus' return on equity of 29.32% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Viatris	-2.04%	19.04%	7.62%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Summary

Lantheus beats Viatris on 11 of the 16 factors compared between the two stocks.

Get Lantheus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNTH vs. The Competition

Export

Metric	Lantheus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.15B	$8.65B	$6.92B	$12.59B
Dividend Yield	N/A	2.45%	2.66%	6.52%
P/E Ratio	24.78	16.61	27.35	24.81
Price / Sales	4.34	8.21	507.73	89.92
Price / Cash	17.21	18.40	29.65	49.23
Price / Book	6.26	3.63	11.06	6.50
Net Income	$233.56M	$226.17M	$3.57B	$336.03M
7 Day Performance	-6.17%	3.24%	2.56%	2.68%
1 Month Performance	1.82%	2.34%	7.39%	5.50%
1 Year Performance	29.81%	1.28%	34.13%	25.01%

Lantheus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNTH Lantheus	2.5929 of 5 stars	$102.82 -6.4%	$101.86 -0.9%	+38.7%	$7.15B	$1.54B	24.78	1,193
MRNA Moderna	1.1695 of 5 stars	$69.70 +3.6%	$37.13 -46.7%	+161.8%	$26.69B	$1.94B	N/A	4,700
ROIV Roivant Sciences	1.8211 of 5 stars	$34.73 +1.9%	$33.59 -3.3%	+223.9%	$24.51B	$8.26M	N/A	860
BNTX BioNTech	3.8617 of 5 stars	$94.26 +3.3%	$129.56 +37.5%	-11.0%	$23.07B	$2.81B	N/A	7,807	Gap Down
INSM Insmed	3.6761 of 5 stars	$104.74 +1.3%	$211.86 +102.3%	+13.3%	$22.41B	$606.42M	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNTH) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantheus (LNTH) Competitors